PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

Active, not recruiting

Conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Interventions: Drug: Tafamidis

First Posted Date: 2024-05-01

Last Posted Date: 2025-05-08

Lead Sponsor: Pfizer

Target Recruit Count: 50

Registration Number: NCT06393465

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Oral [14C] PF-06821497
Drug: Oral PF-06821497
Drug: IV [14C] PF-06821497

First Posted Date: 2024-04-30

Last Posted Date: 2025-01-23

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT06392230

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Ritlecitinib

First Posted Date: 2024-04-17

Last Posted Date: 2024-08-28

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT06369454

Locations: 🇺🇸
Scintipharma - Lexington - Maywick View Lane, Lexington, Kentucky, United States

Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)

Recruiting

Conditions: Eczema
Immune System Diseases
Skin Diseases
Dermatitis, Atopic
Janus Kinase Inhibitors
Dermatitis

First Posted Date: 2024-04-08

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 200

Registration Number: NCT06353087

Locations: 🇨🇳
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
🇨🇳
Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan
🇨🇳
MacKay Memorial Hospital, Taipei City, Taiwan

and more 5 locations

A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: single dose of vepdegestrant as tablet formulation (Treatment A)
Drug: single dose of vepdegestrant as tablet formulation (Treatment B)
Drug: single dose of vepdegestrant as tablet formulation (Treatment C)

First Posted Date: 2024-04-04

Last Posted Date: 2024-10-01

Lead Sponsor: Pfizer

Target Recruit Count: 52

Registration Number: NCT06347861

Locations: 🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States

A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function

Phase 1

Completed

Conditions: Liver Diseases

Interventions: Drug: Osivelotor

First Posted Date: 2024-04-01

Last Posted Date: 2025-01-10

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT06340347

Locations: 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸
Genesis Clinical Research, LLC, Tampa, Florida, United States
🇺🇸
Thomas Jefferson University-Pharmacology, Physiology and Cancer Biology, Philadelphia, Pennsylvania, United States

A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07054894 or placebo

First Posted Date: 2024-03-25

Last Posted Date: 2024-08-05

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT06327880

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants

Phase 3

Active, not recruiting

Conditions: Respiratory Syncytial Virus

Interventions: Biological: RSVpreF vaccine
Biological: Placebp

First Posted Date: 2024-03-22

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 343

Registration Number: NCT06325657

Locations: 🇿🇦
Setshaba Research Centre, Tshwane, Gauteng, South Africa
🇿🇦
Synergy Biomed Research Institute, East London, Eastern CAPE, South Africa
🇿🇦
Josha Research, Bloemfontein, FREE State, South Africa

and more 11 locations

A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Active, not recruiting

Conditions: Transthyretin Amyloid Cardiomyopathy

Interventions: Drug: Tafamidis 61 milligrams

First Posted Date: 2024-03-20

Last Posted Date: 2025-02-14

Lead Sponsor: Pfizer

Target Recruit Count: 13

Registration Number: NCT06321523

Locations: 🇰🇷
Pfizer, Seoul, Korea, Republic of

A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.

Active, not recruiting

Conditions: Lung Cancer

First Posted Date: 2024-03-20

Last Posted Date: 2025-06-05

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT06321510

Locations: 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy